Difei Yang

Difei Yang of Mizuho Securities inquired about the typical timeframe to observe reduced ventilator utilization in AT132-treated patients and whether the higher dose might accelerate this onset of action.

Answer

Chairman and CEO Matt Patterson explained that respiratory function improves rapidly within weeks, leading to ventilator use reductions over the first 24 weeks. He noted that while the higher dose showed better results in tissue histopathology, a meaningful difference in the speed of clinical outcomes like ventilator reduction was not observed between the two doses.

Difei Yang of Mizuho Securities inquired about the extent of manufacturing process changes needed for new programs and whether any Cohort 2 biopsy data for MTM would be presented at the upcoming ASGCT meeting.

Answer

President and CEO Matthew Patterson emphasized that their manufacturing process is a platform technology, completely applicable to new programs like Pompe and AT720 with no fundamental changes needed. He confirmed that the ASGCT presentation will include biopsy data, including 48-week data from Cohort 1 and likely 24-week data from at least the first patient in Cohort 2.